Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis: Observations from the Dallas Heart Study

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2009 Apr 16

PMID 19366975

Citations 45

Authors

Jason B Lindsey

James A de Lemos

Francesco Cipollone

Colby R Ayers

Anand Rohatgi

David A Morrow

Amit Khera

Darren K McGuire

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the association between circulating soluble receptor for advanced glycation end products (sRAGE) and coronary atherosclerosis.

Research Design And Methods: Using data from the Dallas Heart Study, a probability-based population sample, the association between plasma levels of sRAGE and coronary artery calcium (CAC) was assessed among 2,571 subjects with complete imaging and sRAGE data.

Results: An inverse graded association was observed between sRAGE quartiles and CAC, with CAC prevalence of 28.5% in quartile 1 compared with 15.7% in quartile 4 (P < 0.0001). After multivariable adjustment, the associations between sRAGE levels in the first and second quartiles (versus fourth quartile) and CAC remained statistically significant (adjusted odds ratio 1.71 [95% CI 1.2-2.4] and 1.5 [1.0-2.1], respectively).

Conclusions: sRAGE is a novel biomarker that is inversely associated with coronary atherosclerosis. The role of sRAGE in the pathobiology of atherosclerosis and its potential prognostic and therapeutic implications warrant further investigation.

Citing Articles

AGE-RAGE Axis and Cardiovascular Diseases: Pathophysiologic Mechanisms and Prospects for Clinical Applications.

Wang B, Jiang T, Qi Y, Luo S, Xia Y, Lang B Cardiovasc Drugs Ther. 2024; .

PMID: 39499399 DOI: 10.1007/s10557-024-07639-0.

AGE-RAGE Stress and Coronary Artery Disease.

Prasad K Int J Angiol. 2021; 30(1):4-14.

PMID: 34025091 PMC: 8128491. DOI: 10.1055/s-0040-1721813.

Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.

Pratte K, Curtis J, Kechris K, Couper D, Cho M, Silverman E Respir Res. 2021; 22(1):127.

PMID: 33906653 PMC: 8076883. DOI: 10.1186/s12931-021-01686-z.

Revealing the role of the human blood plasma proteome in obesity using genetic drivers.

Zaghlool S, Sharma S, Molnar M, Matias-Garcia P, Elhadad M, Waldenberger M Nat Commun. 2021; 12(1):1279.

PMID: 33627659 PMC: 7904950. DOI: 10.1038/s41467-021-21542-4.

Low Soluble Receptor for Advanced Glycation End Products Precedes and Predicts Cardiometabolic Events in Women With Rheumatoid Arthritis.

Nadali M, Lyngfelt L, Erlandsson M, Toyra Silfversward S, Andersson K, Bokarewa M Front Med (Lausanne). 2021; 7:594622.

PMID: 33585503 PMC: 7876441. DOI: 10.3389/fmed.2020.594622.

References

Lindsey J, Cipollone F, Abdullah S, McGuire D . Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009; 6(1):7-14. DOI: 10.3132/dvdr.2009.002. View

Jain T, Peshock R, McGuire D, Willett D, Yu Z, Yu Z . African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. J Am Coll Cardiol. 2004; 44(5):1011-7. DOI: 10.1016/j.jacc.2004.05.069. View

Park L, Raman K, Lee K, Lu Y, Ferran Jr L, Chow W . Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998; 4(9):1025-31. DOI: 10.1038/2012. View

Yonekura H, Yamamoto Y, Sakurai S, Petrova R, Abedin M, Li H . Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2002; 370(Pt 3):1097-109. PMC: 1223244. DOI: 10.1042/BJ20021371. View

Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong L . RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis. 2005; 185(1):70-7. DOI: 10.1016/j.atherosclerosis.2005.06.013. View

Victor R, Haley R, Willett D, Peshock R, Vaeth P, Leonard D . The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol. 2004; 93(12):1473-80. DOI: 10.1016/j.amjcard.2004.02.058. View

Park I, Yeon S, Youn J, Choi J, Sasaki N, Choi I . Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol. 2004; 40(16):1203-11. DOI: 10.1016/j.molimm.2003.11.027. View

Hudson B, Harja E, Moser B, Schmidt A . Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol. 2005; 25(5):879-82. DOI: 10.1161/01.ATV.0000164804.05324.8b. View

Bucciarelli L, Wendt T, Qu W, Lu Y, Lalla E, Rong L . RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002; 106(22):2827-35. DOI: 10.1161/01.cir.0000039325.03698.36. View

10.

Brett J, Schmidt A, Yan S, Zou Y, Weidman E, Pinsky D . Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993; 143(6):1699-712. PMC: 1887265. View

11.

Falcone C, Emanuele E, DAngelo A, Buzzi M, Belvito C, Cuccia M . Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005; 25(5):1032-7. DOI: 10.1161/01.ATV.0000160342.20342.00. View

12.

Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S . Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005; 25(12):2587-93. DOI: 10.1161/01.ATV.0000190660.32863.cd. View